Skip to main content

Critical Care Reviews Newsletter

Newsletter 487 |  April 12th 2021

RADAR2 trial result presentation

Dr Jon Silversides (Belfast) presents the results of the RADAR2 trial at eCCR21

Welcome to the 487th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

It's a small newsletter, due to both Easter and a lack of available time for me to watch the literature as usual.

The highlights of this week's edition are two case series on thromboses after vaccination with the Oxford-AstraZeneca COVID-19 vaccine and a systematic review on the impact of differences in acute respiratory distress syndrome randomised controlled trial inclusion and exclusion criteria. There are also guidelines on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) & multisystem inflammatory syndrome in children associated with SARS-CoV-2; narrative reviews on COVID-19 & long-term consequences of acute kidney injury; an editorial on identifying what matters to survivors of critical illness; and a commentary on nanobodies for Covid-19.

If you only have time to read one review article this week, try this one on acute kidney injury before and after kidney transplantation.

eCCR21 Videos

Our ongoing release of the edited videos from the Critical Care Reviews Meeting 2021 (eCCR21) continues with the RADAR2 trial result presentation, investigating the effects of active deresuscitation after resuscitation.

I hope you find this newsletter useful.


Until next week

Rob

 

 

Supported by the Health Research Board